JP Morgan Chase
INO icon

JP Morgan Chase’s Inovio Pharmaceuticals INO Stock Holding History

JP Morgan Chase’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,333
Closed -$1.13M – 5767
2020
Q3 		$1.13M Buy
+8,333
New +$1.74M ﹤0.01% 3580

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's INO Position: Q2 2026 in Review

JP Morgan Chase reduced its Inovio Pharmaceuticals (INO) stake by 99% in Q2 2026, selling an estimated $6.45K and leaving 46 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #7583.

JP Morgan Chase first reported a position in INO in Q2 2013 and has held it in 49 quarters since. The position peaked at $31.9M in Q2 2021. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • JP Morgan Chase held 46 shares of Inovio Pharmaceuticals worth $52 as of Q2 2026.
  • JP Morgan Chase sold 5,439 Inovio Pharmaceuticals shares in Q2 2026, an estimated $6.45K.
  • Inovio Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7583 holding.
  • JP Morgan Chase first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • JP Morgan Chase's Inovio Pharmaceuticals position peaked at $31.9M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.